	US 12,215,362 B2
	Pharmaceutical composition for prevention or treatment of heart failure
Tae Hwan Kwak, Yongin-si (KR); and Woo Jin Park, Gwangju (KR)
Assigned to BETHPHAGEN INC., Gwangju (KR)
Appl. No. 16/651,779
Filed by BETHPHAGEN INC., Gwangju (KR)
PCT Filed Sep. 28, 2018, PCT No. PCT/KR2018/011521 § 371(c)(1), (2) Date Mar. 27, 2020, PCT Pub. No. WO2019/066548, PCT Pub. Date Apr. 4, 2019.
Claims priority of application No. 10-2017-0127442 (KR), filed on Sep. 29, 2017.
Prior Publication US 2020/0239862 A1, Jul. 30, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 9/00 (2006.01); A61K 35/76 (2015.01); A61K 38/17 (2006.01); A61K 48/00 (2006.01); C07K 14/47 (2006.01); C12N 7/00 (2006.01); C12N 9/14 (2006.01); C12N 15/85 (2006.01); C12N 15/86 (2006.01); G01N 33/68 (2006.01); A61K 38/00 (2006.01)

CPC C12N 9/14 (2013.01) [A61K 35/76 (2013.01); A61K 38/1738 (2013.01); A61K 38/179 (2013.01); A61K 48/0066 (2013.01); A61P 9/00 (2018.01); C07K 14/47 (2013.01); C12N 7/00 (2013.01); C12N 15/85 (2013.01); C12N 15/86 (2013.01); C12Y 306/03008 (2013.01); G01N 33/6893 (2013.01); A61K 38/00 (2013.01); A61K 48/00 (2013.01); C12N 2750/14143 (2013.01); C12N 2800/107 (2013.01); G01N 2800/325 (2013.01)]

27 Claims

1. A gene construct comprising:

(i) a nucleotide sequence encoding sarcoplasmic/endoplasmic reticulum Ca²+ATPase 2a (SERCA2a) protein; and

(ii) a nucleotide sequence encoding cellular communication network factor 5 (CCN5) protein.